Production (Stage)
Cryo-Cell International, Inc.
CCEL
$4.83
$0.030.63%
AMEX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.33% | 2.05% | 1.94% | 1.93% | 1.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.33% | 2.05% | 1.94% | 1.93% | 1.52% |
| Cost of Revenue | -35.91% | -35.24% | 40.82% | 38.05% | 38.49% |
| Gross Profit | 26.43% | 25.58% | -12.61% | -12.13% | -13.10% |
| SG&A Expenses | 6.22% | 8.40% | 9.96% | 9.19% | 10.16% |
| Depreciation & Amortization | -26.73% | -56.98% | -49.35% | -41.66% | -21.88% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.13% | -10.77% | 19.11% | 20.04% | 22.98% |
| Operating Income | 526.92% | 1,637.55% | -103.06% | -105.66% | -120.42% |
| Income Before Tax | 118.45% | 120.98% | -479.78% | -548.19% | -508.09% |
| Income Tax Expenses | 159.59% | 162.51% | -559.14% | -731.92% | -703.37% |
| Earnings from Continuing Operations | 101.32% | 104.22% | -456.17% | -505.57% | -459.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 101.32% | 104.22% | -456.17% | -505.57% | -459.64% |
| EBIT | 526.92% | 1,637.55% | -103.06% | -105.66% | -120.42% |
| EBITDA | 2,747.79% | 289.53% | -88.89% | -89.55% | -97.19% |
| EPS Basic | 101.31% | 104.14% | -460.18% | -513.21% | -467.26% |
| Normalized Basic EPS | 212.89% | 250.38% | -130.37% | -123.60% | -156.87% |
| EPS Diluted | 100.78% | 104.02% | -463.89% | -515.19% | -474.71% |
| Normalized Diluted EPS | 210.03% | 246.76% | -131.82% | -124.77% | -157.40% |
| Average Basic Shares Outstanding | -2.56% | -2.52% | -2.53% | -2.16% | -1.87% |
| Average Diluted Shares Outstanding | -1.84% | -1.91% | -1.92% | -1.60% | -1.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |